Fabris E, et al. - Given that an effective antithrombotic regimen is important for patients with diabetes mellitus (DM) patients due to the high platelet reactivity and a prothrombotic condition observed in this population, researchers investigated the impact of DM on cardiovascular outcomes. They also assessed how pre-hospital administration of ticagrelor may affect these outcomes in a subgroup of patients with DM and ST-elevation myocardial infarction (STEMI). Participants included 1,630 patients with STEMI enrolled in the ATLANTIC trial who had primary percutaneous coronary intervention (PCI). Among these patients, 13.1% also had DM. Findings demonstrated that DM is independently related to poor myocardial reperfusion and worse 30-day clinical outcomes. Additionally, there was no significant interaction between pre-hospital vs in-hospital ticagrelor administration and DM status.